A Pharmacokinetic Study of L-697,661 Alone and in Combination With Zidovudine

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE1

Total Enrollment

27 participants

Study Classification

INTERVENTIONAL

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Part 1: To study the potential safety and pharmacokinetic (blood level) effects of zidovudine (AZT) on L-697,661; to obtain additional pharmacokinetic information in humans with L-697,661; to study the effect of L-697,661 on hepatic enzyme induction. Part 2: To begin a study of the antiviral activity of L-697,661.

L-697,661 is a newly identified compound that inhibits HIV replication (reproduction and growth) in cell culture. It works together with AZT against HIV.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

A Study of Zidovudine Plus Acyclovir in HIV-Infected Patients

NCT00001010

HIV Infections

COMPLETED PHASE1

The Effectiveness of Three Drug Combinations in HIV-Infected Patients Who Have Taken Zidovudine for More Than 12 Weeks

NCT00001063

HIV Infections

COMPLETED PHASE2

A Phase II Double-Blind Study of Two Doses of SC-49483 in Combination With Zidovudine (ZDV) Versus ZDV

NCT00000791

HIV Infections

COMPLETED PHASE2

A Study of Zidovudine in HIV-Infected Patients With Kidney Problems

NCT00000685

HIV Infections Kidney Disease

WITHDRAWN PHASE1

A Phase I Study to Evaluate the Pharmacokinetics, Safety and Antiviral Effects of Concurrent Administration of Zidovudine (AZT) and 2'3'-Dideoxyinosine (ddI) in Patients With Human Immunodeficiency Virus (HIV)

NCT00002014

HIV Infections

COMPLETED PHASE1

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

L-697,661 is a newly identified compound that inhibits HIV replication (reproduction and growth) in cell culture. It works together with AZT against HIV.

Part 1: Twelve patients are randomly assigned to one of two groups. Group 1 patients receive AZT for 7 days, followed by AZT plus L-697,661 with food for 56 days. Group 2 patients receive no drug for 7 days, followed by L-697,661 with food for 56 days. Antipyrine is administered 1 hour prior to study drug on days 8, 22, and 35.

Part 2: Fifteen patients receive L-697,661 with food, for 8 weeks. Therapy with L-697,661 may be extended beyond 8 weeks for up to 24 weeks.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

HIV Infections

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

L-697,661

Intervention Type DRUG

Zidovudine

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

Patients must have:

* HIV infection.

Prior Medication: Included:

* Patients in Part 1 must have received no previous zidovudine (AZT) or a stable dose of at least 500 mg/day without evidence of toxicity.
* Patients in Part 2 must have received no previous AZT or = or \> 300 mg/day for \< 6 consecutive weeks within 1 year prior to study entry.

Exclusion Criteria

Co-existing Condition:

Patients with the following conditions or symptoms are excluded:

* Acute HIV-related opportunistic infection requiring ongoing treatment.
* Diarrhea defined as 3 or more liquid stools/day for one week.
* Wilson's or Gilbert's disease, porphyria, or other chronic or acute hepatic disease.
* Potentially life-threatening allergic reactions to any of the components of zidovudine.
* Acute or chronic medical conditions that in the opinion of the investigator would place patient at risk by participation in this study.

Concurrent Medication:

Excluded:

* Systemic bronchodilators, acetaminophen, aspirin.

Prior Medication:

Excluded:

* Didanosine (ddI) or dideoxycytidine (ddC) within 14 days prior to entry.
* Immune modulators or investigational drugs within 30 days prior to entry.
* Drugs known to induce hepatocellular enzymes, such as phenobarbital, phenytoin, warfarin, ketoconazole, and oral contraceptives, within 30 days prior to entry.

Patients in Part 2 only:

Excluded:

* Zidovudine within 4 weeks prior to receiving first dose of study drug.

Risk Behavior:

Excluded:

* Patients who the investigator feels would not comply with study requirements.

Patients may not have the following prior conditions:

* Acute or chronic medical conditions that in the opinion of the investigator would place patient at risk by participation in this study.
* Potentially life-threatening allergic reactions to any of the components of zidovudine.

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No